Genc, SelinEvren, BahriYigit, Onur SelcukSahin, IbrahimDayanan, RamazanKlisic, AleksandraErturk, Ayse2026-04-042026-04-0420241424-8247https://doi.org/10.3390/ph17111553https://hdl.handle.net/11616/108492Background/Objectives: The antidiabetic effect of SGLT2 inhibitors (SGLT2-is) is based on their ability to increase glucose excretion through urine by inhibiting the kidney-resident SGLT2 protein. Euglycemic diabetic ketoacidosis (EuDKA) is an uncommon but potentially life-threatening adverse effect of these medications, which are notable for their antidiabetic, cardiovascular, and renal protective properties. This study aimed to clarify the impact of SGLT2-is on demographic, clinical, and biochemical characteristics in patients with DKA. Methods: A total of 51 individuals with a diagnosis of DKA were included in the trial; 19 of these patients were treated with SGLT2-is, while 32 were not. Patients diagnosed with DKA and treated with SGLT2-is were compared to those not treated with the medication in terms of clinical, biochemical, and laboratory characteristics. Results: The age of patients utilizing SGLT2-is was statistically considerably greater than that of non-users (p < 0.001). EuDKA was exclusively noted in the SGLT2-is cohort (p = 0.005). Urinary tract infections, vulvovaginitis, and genitourinary infections were substantially more prevalent among SGLT2-i users compared with non-users among both women and the overall patient group (p = 0.036, p = 0.001, p = 0.005, p = 0.003, respectively). Plasma glucose concentrations were significantly higher in SGLT2-i non-users (p = 0.006). Chloride (Cl-) concentrations were elevated among SGLT2-i users (p = 0.036). Conclusions: The study findings indicate that SGLT2 inhibitors may substantially influence age, serum chloride, EuDKA, and the occurrence of genitourinary infections in individuals with DKA.eninfo:eu-repo/semantics/openAccessdiabetic ketoacidosis (DKA)euglycemic diabetic ketoacidosis (euDKA)genitourinary infection (GUI)latent autoimmune diabetes in adults (LADA)sodium-glucose co-transporter-2 inhibitor (SGLT2-i)type 1 diabetes mellitus (T1DM)Article17113959846310.3390/ph171115532-s2.0-85210438281Q1WOS:001367145700001Q10000-0002-8510-30460000-0002-4325-15340000-0001-6413-91650000-0001-7870-0996